News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
773,050 Results
Type
Article (58113)
Company Profile (449)
Press Release (714488)
Section
Business (224150)
Career Advice (2707)
Deals (38124)
Drug Delivery (122)
Drug Development (87539)
Employer Resources (177)
FDA (17439)
Job Trends (16399)
News (378096)
Policy (36196)
Tag
Academia (2887)
Alliances (55322)
Alzheimer's disease (1404)
Approvals (17401)
Artificial intelligence (234)
Bankruptcy (383)
Best Places to Work (12378)
Biotechnology (305)
Breast cancer (238)
Cancer (1819)
Cardiovascular disease (146)
Career advice (2269)
CAR-T (135)
Cell therapy (392)
Clinical research (70109)
Collaboration (720)
Compensation (382)
COVID-19 (2803)
C-suite (173)
Data (1672)
Diabetes (228)
Diagnostics (6693)
Earnings (91782)
Employer resources (155)
Events (123133)
Executive appointments (601)
FDA (18386)
Funding (646)
Gene therapy (279)
GLP-1 (752)
Government (4834)
Healthcare (20192)
Infectious disease (2924)
Inflammatory bowel disease (133)
Interviews (466)
IPO (17335)
Job creations (4508)
Job search strategy (1920)
Layoffs (502)
Legal (8998)
Lung cancer (269)
Manufacturing (263)
Medical device (14217)
Medtech (14222)
Mergers & acquisitions (21158)
Metabolic disorders (614)
Neuroscience (1858)
NextGen: Class of 2025 (7246)
Non-profit (4904)
Northern California (2142)
Obesity (342)
Opinion (250)
Patents (172)
People (62555)
Phase I (21821)
Phase II (30744)
Phase III (23000)
Pipeline (737)
Postmarket research (2944)
Preclinical (9472)
Radiopharmaceuticals (261)
Rare diseases (354)
Real estate (6825)
Regulatory (24228)
Research institute (2591)
Resumes & cover letters (435)
Southern California (1848)
Startups (4080)
United States (19469)
Vaccines (702)
Weight loss (256)
Date
Last 7 days (638)
Last 30 days (2645)
Last 365 days (36502)
2025 (4761)
2024 (37372)
2023 (42219)
2022 (53609)
2021 (58335)
2020 (57075)
2019 (50281)
2018 (38161)
2017 (35558)
2016 (35785)
2015 (41863)
2014 (36218)
2013 (31922)
2012 (33683)
2011 (33991)
2010 (32430)
Location
Africa (988)
Arizona (231)
Asia (45437)
Australia (7549)
California (4957)
Canada (1747)
China (416)
Colorado (228)
Connecticut (252)
Europe (100497)
Florida (710)
Georgia (171)
Illinois (505)
Indiana (278)
Maryland (795)
Massachusetts (3824)
Michigan (218)
Minnesota (353)
New Jersey (1404)
New York (1403)
North Carolina (941)
Northern California (2142)
Ohio (184)
Pennsylvania (1127)
South America (1363)
Southern California (1848)
Texas (727)
Utah (152)
Washington State (498)
773,050 Results for "otsuka pharmaceutical development and commercialization inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Otsuka to Terminate Development of AVP-786
Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. announce termination of development of the novel compound AVP-786, which was in development as a potential treatment for patients with agitation associated with dementia due to Alzheimer’s disease.
May 22, 2024
·
2 min read
Biotech Beach
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Ionis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka obtains exclusive rights across the Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema.
June 18, 2024
·
5 min read
Drug Development
Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) today presented results from the Phase II (Trial 061) and Phase III trials (Trial 071 and 072) evaluating the safety and efficacy of brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD).
May 28, 2024
·
20 min read
Press Releases
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
August 1, 2024
·
6 min read
Business
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn
Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn.
April 1, 2024
·
12 min read
Deals
Otsuka Pays Up to $1.1B to Buy Jnana, Adds Drug Discovery Capabilities
With an upfront $800 million payment and $325 million in potential milestones, Otsuka Pharmaceutical is acquiring Jnana Therapeutics’ drug discovery platform and rare disease candidate, the companies announced Thursday.
August 1, 2024
·
2 min read
·
Nick Paul Taylor
Press Releases
Health Canada Approves Otsuka and Lundbeck’s (Pr)ABILIFY ASIMTUFII® (aripiprazole), the First-and-Only, Once-Every-Two-Months, Long-Acting Injectable (LAI) Treatment for Schizophrenia and for Maintenance Monotherapy of Bipolar I Disorder in Adults
January 17, 2025
·
7 min read
Drug Development
Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease
Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and our parent company Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce topline results of the phase 3 clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer’s disease (Trial 17-AVP-786-305; NCT03393520).
February 12, 2024
·
4 min read
Drug Development
Otsuka Drops Alzheimer’s Agitation Drug Following Phase III Failure
Otsuka Pharmaceuticals announced Wednesday it is ending development of drug candidate AVP-786 after failing to improve agitation associated with dementia due to Alzheimer’s disease.
May 22, 2024
·
1 min read
·
Kate Goodwin
Business
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE).
December 18, 2023
·
5 min read
1 of 77,305
Next
